CD25-positive cutaneous T-cell lymphoma

CD25-positive cutaneous T-cell lymphoma refers to a clinicopathologic subset of non-Hodgkin T-cell lymphomas characterized by the infiltration of malignant mature T lymphocytes into the skin that express CD25, the alpha subunit of the interleukin-2 (IL-2) receptor Primarily affecting adult integumentary tissue, the disease encompasses entities such as mycosis fungoides and Sézary syndrome, presenting clinically with persistent pruritic patches, infiltrated plaques, cutaneous tumors, or generaliz...

CD25-positive cutaneous T-cell lymphoma refers to a clinicopathologic subset of non-Hodgkin T-cell lymphomas characterized by the infiltration of malignant mature T lymphocytes into the skin that express CD25, the alpha subunit of the interleukin-2 (IL-2) receptor Primarily affecting adult integumentary tissue, the disease encompasses entities such as mycosis fungoides and Sézary syndrome, presenting clinically with persistent pruritic patches, infiltrated plaques, cutaneous tumors, or generaliz...

CD25-positive cutaneous T-cell lymphoma refers to a clinicopathologic subset of non-Hodgkin T-cell lymphomas characterized by the infiltration of malignant mature T lymphocytes into the skin that express CD25, the alpha subunit of the interleukin-2 (IL-2) receptor

Primarily affecting adult integumentary tissue, the disease encompasses entities such as mycosis fungoides and Sézary syndrome, presenting clinically with persistent pruritic patches, infiltrated plaques, cutaneous tumors, or generalized erythroderma

Pathophysiologically, the tumor cells demonstrate skin tropism, and the surface expression of CD25 marks cellular activation and high-affinity IL-2 receptor assembly, which serves as both an adverse prognostic biomarker and a selective therapeutic molecular target

Pathophysiologically, the tumor cells demonstrate skin tropism, and the surface expression of CD25 marks cellular activation and high-affinity IL-2 receptor assembly, which serves as both an adverse prognostic biomarker and a selective therapeutic molecular target